GLP-1 in dialysis and end-stage kidney disease: dosing, timing and what evidence exists

TLDR. Patients on dialysis were excluded from the FLOW trial, so direct evidence for GLP-1 in end-stage renal disease (ESRD) is thin. Off-label use in ESRD is growing among obesity-medicine and nephrology specialists. Dosing protocols vary: some start at the standard low dose with slow titration, others reduce by 25 to 50 percent. The pharmacokinetics support standard dosing (renal clearance of semaglutide is minimal), but tolerability is lower in this population due to gastroparesis prevalence and electrolyte instability. CGM-equivalent monitoring is recommended.

The FLOW trial established semaglutide as protective against kidney-disease progression in T2D patients with CKD stages 3-4. Patients on dialysis (CKD stage 5, ESRD) were explicitly excluded from FLOW. Off-label GLP-1 use in ESRD is growing in 2026, but the evidence base is thin and the dosing protocols are still being developed by clinical experience rather than trial data.

Why dialysis patients were excluded

Two reasons:

• Drug clearance: semaglutide is partially cleared by the kidneys. In ESRD with no native kidney function, clearance is altered and steady-state concentrations may differ from the standard population.
• Mortality: ESRD patients have substantially higher all-cause mortality regardless of intervention. Trials in this population require larger sample sizes and longer follow-up than the GLP-1 program had committed to at the time.

The result: no FDA-label data on ESRD dosing. Use in this population is off-label, supervised and individualised.

What the limited evidence suggests

Several case series and small observational studies have characterised semaglutide use in dialysis patients:

• Drug exposure (AUC) is roughly 20-40% higher in dialysis patients vs the standard population at the same dose
• Patients on hemodialysis 3x/week show meaningful weight loss (7-12% of body weight at 6 months) on standard semaglutide dosing
• GI side effects appear at higher rates than in non-dialysis patients, consistent with higher drug exposure
• No accelerated decline in residual renal function observed (most ESRD patients have minimal residual function)

The dosing protocols obesity-medicine and nephrology specialists use

The general approach in published case series and conference presentations:

• Start at 0.25 mg semaglutide weekly (the standard starting dose)
• Titrate up every 6-8 weeks instead of every 4 weeks, slower titration to account for higher drug exposure and increased GI side-effect risk
• Maintenance dose typically capped at 1.7 mg rather than 2.4 mg, reflecting the elevated drug exposure
• Inject on non-dialysis days, most clinicians prefer the day after dialysis to allow for steady-state monitoring without dialysis-day fluid shifts
• Monthly labs including potassium, phosphorus and PTH, GLP-1 doesn't directly affect these but appetite changes may shift dietary intake meaningfully

Tirzepatide has even less ESRD data than semaglutide. Most nephrologists prefer semaglutide in ESRD due to the larger evidence base.

Volume and weight considerations

Dialysis patients track dry weight (post-dialysis target weight) carefully. GLP-1 weight loss alters dry weight, which means your dialysis prescription (target ultrafiltration volume) needs to be adjusted as you lose. This requires active coordination with your dialysis nephrologist; don't pursue GLP-1 in ESRD without that coordination.

Who should NOT use GLP-1 in ESRD

• Patients with active intradialytic hypotension
• Patients with severe gastroparesis (already common in long-standing ESRD diabetics)
• Patients on the kidney transplant list with active workup (typically discontinued 4-8 weeks pre-transplant)
• Patients with active malnutrition or low albumin

Programs equipped for ESRD coordination

Most telehealth GLP-1 programs are not equipped for ESRD prescribing because the clinical complexity requires nephrology coordination. Three programs in our chart can handle this with sufficient depth:

• Knownwell, full primary-care integrated model. Strongest pick for ESRD coordination.
• Form Health, obesity-medicine specialists who'll coordinate with nephrology.
• 9amHealth, cardiometabolic-focused, common comorbidity overlap.

For most ESRD patients, the best path is to discuss GLP-1 with your existing nephrology team rather than starting through a telehealth program. The dosing decisions require integration with your dialysis prescription, which telehealth alone cannot provide.

For the broader kidney evidence base see our FLOW trial deep-dive.

Frequently asked questions

Can I use GLP-1 if I am on dialysis?

Off-label only. The FLOW trial excluded dialysis patients, so there is no FDA-supported evidence for GLP-1 in ESRD. Some nephrology and obesity-medicine specialists prescribe off-label in selected dialysis patients, with reduced starting dose and slower titration. The clinical evidence is observational and the patient population is small.

Does my kidney function change the GLP-1 dose I need?

Pharmacokinetically, no. Semaglutide is cleared by proteolysis rather than renal excretion, so kidney function affects drug clearance minimally. The clinical reasons to reduce dose in ESRD are different: gastroparesis is more common, electrolyte balance is fragile, and tolerability is lower. Many specialists use a 25 to 50 percent dose reduction empirically for safety margin.

What side effects are different in dialysis patients on GLP-1?

Gastroparesis-like symptoms are more common because dialysis patients have higher background rates of slowed gastric emptying. Volume status matters more: GI side effects (vomiting, diarrhea) can shift fluid balance and electrolytes meaningfully. Hypoglycemia risk is higher if the patient is also on insulin or sulfonylureas. Close monitoring is essential.

Is tirzepatide safer than semaglutide for dialysis patients?

Unclear from existing data. Both medications work similarly mechanistically. Tirzepatide may produce more aggressive weight loss, which is a mixed effect in dialysis patients (good for obesity but risky if it destabilizes nutritional status). Most off-label ESRD use has been with semaglutide because the FLOW data, even excluding dialysis, gives more reassurance about the kidney population broadly.

Will my nephrologist prescribe GLP-1?

Some will, in coordination with obesity medicine. The growing pattern is co-prescribing: nephrology monitors kidney and electrolyte status, obesity medicine handles GLP-1 titration and follow-up. Patients without an established nephrology-obesity coordination should ask for it before starting. Solo nephrologist prescribing in ESRD is less common but happens in specialist centers.